Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: Results of APL 93 trial

British Journal of Haematology

Volumn 111, Issue 3, 2000, Pages 801-806

  De Botton, S ^a   Chevret, S ^b   Sanz, M ^b   Dombret, H ^b   Thomas, X ^b   Guerci, A ^b   Fey, M ^b   Rayon, C ^b   Huguet, F ^b   Sotto, J J ^b   Gardin, C ^b   Makhoul, P C ^b   Travade, P ^b   Solary, E ^b   Fegueux, N ^b   Bordessoule, D ^b   San Miguel, J ^b   Link, H ^b   Desablens, B ^b   Stamatoullas, A ^b   Deconinck, E ^b   Geiser, K ^b   Hess, U ^b   Maloisel, F ^b   Castaigne, S ^b   Preudhomme, C ^b   Chomienne, C ^b   Degos, L ^b   Fenaux, P ^b   more..

^a LILLE UNIVERSITY HOSPITAL   (France)

^b Service des Maladies du Sang   (France)

Author keywords

Acute promyelocytic leukaemia; Additional chromosomal rearrangements; Chromosomes

Indexed keywords

ANTINEOPLASTIC AGENT; RETINOIC ACID;

ACUTE DISEASE; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME 15; CHROMOSOME 17; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; CLONAL ANERGY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; TRISOMY 8;

ADULT; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 12; CHROMOSOMES, HUMAN, PAIR 15; CHROMOSOMES, HUMAN, PAIR 16; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 6; CHROMOSOMES, HUMAN, PAIR 7; CHROMOSOMES, HUMAN, PAIR 8; CHROMOSOMES, HUMAN, PAIR 9; COHORT STUDIES; CYTARABINE; DAUNORUBICIN; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE; TRANSLOCATION, GENETIC; TRETINOIN; TRISOMY;

EID: 0034494569     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2000.02442.x     Document Type: Article

References (31)

1. Proposals for the classification of the acute leukemias
2. A variant from of hypergranular promyelocytic leukemia (M3)
3. Cytogenetic studies in acute promyelocytic leukemia: A survey of secondary chromosomal abnormalities
4. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid. Results of the randomized MRC trial
5. Regression models and life-tables (with discussion)
6. The PML-RAR alpha fusion mRNA generated by the t(15:17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR
7. Combined therapy with all-trans retinoic acid and high-dose chemotherapy in patients with hyperleukocytic acute promyelocytic leukemia and severe visceral hemorrhage
8. All trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia. A pilot study on 26 cases
9. Effect of all trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial
10. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia
11. Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retnoic acid
12. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1612 patients entered into the MRC AML 10 trial
13. Aggressive daunomycin (DNR) therapy improves survival in acute promyelocytic leukemia (APL), a Southwest Oncology Group (SWOG trial)
14. Secondary chromosome aberrations in the acute leukemias
15. Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia
16. Secondary chromosomal abnormalities in acute leukemias
17. Chromosomal translocation t(15:17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor
18. All trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia
19. Non parametric estimation from incomplete observations
20. Evidence for a 15:17 translocation in every patient with acute promyelocytic leukemia
21. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia
22. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and Idarubicin (AIDA) therapy
23. Continuous treatment with all trans RA progressively decreases plasma drug concentrations: Implications for relapse and resistance in acute promyelocytic leukemia
24. Asymptotically efficient rank invariant test procedures (with discussion)
25. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARa-positive acute promyelocytic leukemia
26. Incidence and implication of additional chromosome aberrations in acute promyelocytic leukaemia with translocation t(15:17) (q22:q21): A report on 50 patients
27. Secondary cytogenetic changes in acute promyelocytic leukemia: Prognostic importance in patients treated with chemotherapy alone and association with the iron 3 breakpoint of the PML gene
28. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia
29. All-trans retinoic acid in acute promyelocytic leukemia
30. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemiaz: Impact of leukocytosis, low-dose chemotherapy. PMN/RAR-α isoform, and CD13 expression in patients treated with all-trans retinoic acid